


Targeted Radionuclide Therapies (TRTs)

- Induce DNA damage in tumor cells resulting in cell damage or death
- This mode of action bypasses mechanisms of primary and acquired resistance in most tumors
- Short range of penetration results in limited damage to surrounding normal tissue
- Radionuclides and targeting vector can be adapted to deliver TRTs to a range of tumors


Commercial confidential information to be withheld under 10 CFR 2.390(a)(4)

Trade secrets and commercial or financial information obtained from a person and privileged or confidential



Research Regarding Patient Access

Reasons for Not Referring Patients for Therapy Despite Recommendation



Commercial confidential information to be withheld under 10 CFR 2.390(a)(4)

Trade secrets and commercial or financial information obtained from a person and privileged or confidential


Note: 1,000+ treatment sites are available in the U.S. As of 2014, therapy was available within a 50-mile radius to 96% of the indicated patient population in the U.S.¹

Double-blind survey approach conducted by an independent third-party for an FDA-approved, NCCN Category I therapy.

¹<https://www.prnewswire.com/news-releases/over-1000-medical-sites-in-the-united-states-now-licensed-to-administer-xofigo-radium-ra-223-dichloride-injection-271062181.html>

Research Regarding Patient Access

Reasons for Not Receiving Therapy **Despite Referral**




Commercial confidential information to be withheld under 10 CFR 2.390(a)(4)

Trade secrets and commercial or financial information obtained from a person and privileged or confidential

Double-blind survey approach conducted by an independent third-party for an FDA-approved, NCCN Category I therapy.

Research Regarding Patient Access

Referral Barriers to Prescribing and Administering Therapy




Commercial confidential information to be withheld under 10 CFR 2.390(a)(4)

Trade secrets and commercial or financial information obtained from a person and privileged or confidential


Commercial confidential information to be withheld under 10 CFR 2.390(a)(4)

Trade secrets and commercial or financial information obtained from a person and privileged or confidential



Commercial confidential information to be withheld under 10 CFR 2.390(a)(4)


Trade secrets and commercial or financial information obtained from a person and privileged or confidential



7

Commercial confidential information to be withheld under 10 CFR 2.390(a)(4)


Trade secrets and commercial or financial information obtained from a person and privileged or confidential



8


Commercial confidential information to be withheld under 10 CFR 2.390(a)(4)

Trade secrets and commercial or financial information obtained from a person and privileged or confidential



Commercial confidential information to be withheld under 10 CFR 2.390(a)(4)

Trade secrets and commercial or financial information obtained from a person and privileged or confidential



Commercial confidential information to be withheld under 10 CFR 2.390(a)(4)

Trade secrets and commercial or financial information obtained from a person and privileged or confidential

